Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Whitepapers/App Notes/Posters

Technical bulletin: An updated approach to E&L testing per ISO 10993-18:2020

Posted: 1 July 2021 | | No comments yet

ISO 10993-18:2020 outlines the chemical characterisation tests that manufacturers must undertake to support the biological safety of their medical devices.

Patient safety is the number one priority. Therefore, medical device manufacturers must ensure that their products do not contain any potentially harmful chemicals that might have found their way into formulations during the packaging or storage processes, or that might be leached in a clinical setting.

This is where ISO 10993-18:2020 guidance comes in. It outlines the chemical characterisation (aka E&L) tests that manufacturers must undertake to support the biological safety of their devices.

    To read this technical bulletin in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of SGS Life Sciences

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.